Mikrobiomik launches strategic investment round to advance its first medicine based on the human microbiome
The Biscayan biopharmaceutical company, which plans to launch its first biological medicine into the market in the first half of 2025, will use the funds to expand its manufacturing capacity and accelerate its pipeline projects.
Mikrobiomik, an Asebio partner company that promotes an innovative therapeutic approach based on gut microbiota and plans to launch its first biological drug on the market in the first half of 2025, has launched a strategic investment round to raise between 6 and 10 million euros.
Mikrobiomik has given CaixaBank CIB the exclusive mandate to assist in the search for potential investors for this round of capital, aimed primarily at Venture Capital, both national and international; Corporate Capital; institutional investors and professional Family Offices.
The funds raised will be used mainly to expand Mikrobiomik's manufacturing capacity to meet the expected demand for its biological medicine MBK-01, for the treatment of primary or recurrent Clostridium difficile infection (CDI) as a first indication. It will also help to increase its current staff of 20 people, to accelerate other clinical trials the company has underway and to launch new projects currently in its pipeline.
In the last quarter of 2023, Mikrobiomik successfully completed its Phase III clinical trial with its biologic MBK-01 in the treatment of primary or recurrent Clostridium difficile infection (CDI), the most common infectious cause of nosocomial (hospital-acquired) diarrhoea and the most common cause of antibiotic-associated diarrhoea in the developed world2, affecting more than 500,000 people in the US and some 124,000 in Europe each year.